[go: up one dir, main page]

BRPI0408705A - método para produzir um anticorpo para um polipeptìdeo, anticorpo produzido pelo mesmo, anticorpo ou fragmento de anticorpo que se liga a um polipeptìdeo, métodos para reduzir ou inibir a proliferação ou diferenciação induzida pela il-20 de células hematopoiéticas e progenitores de célula hematopoiética, para reduzir a inflamação induzida pela il-20, para suprimir uma resposta inflamatória em um mamìfero com inflamação, para tratar um mamìfero afligido com uma doença inflamatória, para tratar um condição patológica em um paciente associada com a atividade de il-20 - Google Patents

método para produzir um anticorpo para um polipeptìdeo, anticorpo produzido pelo mesmo, anticorpo ou fragmento de anticorpo que se liga a um polipeptìdeo, métodos para reduzir ou inibir a proliferação ou diferenciação induzida pela il-20 de células hematopoiéticas e progenitores de célula hematopoiética, para reduzir a inflamação induzida pela il-20, para suprimir uma resposta inflamatória em um mamìfero com inflamação, para tratar um mamìfero afligido com uma doença inflamatória, para tratar um condição patológica em um paciente associada com a atividade de il-20

Info

Publication number
BRPI0408705A
BRPI0408705A BRPI0408705-4A BRPI0408705A BRPI0408705A BR PI0408705 A BRPI0408705 A BR PI0408705A BR PI0408705 A BRPI0408705 A BR PI0408705A BR PI0408705 A BRPI0408705 A BR PI0408705A
Authority
BR
Brazil
Prior art keywords
antibody
polypeptide
treat
mammal
inhibiting
Prior art date
Application number
BRPI0408705-4A
Other languages
English (en)
Inventor
Wenfeng Xu
Wayne Kindsvogel
Yasmin A Chandrasekher
Stacey R Dillon
Joyce M Lehner
Anthony W Siadak
Pallavur V Sivakumar
Margaret D Moore
Original Assignee
Zymogenetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33101289&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0408705(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Zymogenetics Inc filed Critical Zymogenetics Inc
Publication of BRPI0408705A publication Critical patent/BRPI0408705A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

"MéTODO PARA PRODUZIR UM ANTICORPO PARA UM POLIPEPTìDEO, ANTICORPO PRODUZIDO PELO MESMO, ANTICORPO OU FRAGMENTO DE ANTICORPO QUE SE LIGA A UM POLIPEPTìDEO, MéTODOS PARA REDUZIR OU INIBIR A PROLIFERAçãO OU DIFERENCIAçãO INDUZIDA PELA IL-20 DE CéLULAS HEMATOPOIéTICAS E PROGENITORES DE CéLULA HEMATOPOIéTICA, PARA REDUZIR A INFLAMAçãO INDUZIDA PELA IL-20, PARA SUPRIMIR UMA RESPOSTA INFLAMATóRIA EM UM MAMìFERO COM INFLAMAçãO, PARA TRATAR UM MAMìFERO AFLIGIDO COM UMA DOENçA INFLAMATóRIA, PARA TRATAR UMA CONDIçãO PATOLóGICA EM UM PACIENTE ASSOCIADA COM A ATIVIDADE DE IL-20". A presente invenção diz respeito a bloquear, inibir, reduzir, antagonizar ou neutralizar a atividade de moléculas peptídicas de IL-20. IL-20 e IL-22 são citocinas que estão envolvidas em processos inflamatórios e doença humana. A presente invenção inclui anticorpos anti-IL-20 e anti-IL22RA e parceiros de ligação, assim como métodos para antagonizar IL-20 usando tais anticorpos e parceiros de ligação.
BRPI0408705-4A 2003-03-24 2004-03-24 método para produzir um anticorpo para um polipeptìdeo, anticorpo produzido pelo mesmo, anticorpo ou fragmento de anticorpo que se liga a um polipeptìdeo, métodos para reduzir ou inibir a proliferação ou diferenciação induzida pela il-20 de células hematopoiéticas e progenitores de célula hematopoiética, para reduzir a inflamação induzida pela il-20, para suprimir uma resposta inflamatória em um mamìfero com inflamação, para tratar um mamìfero afligido com uma doença inflamatória, para tratar um condição patológica em um paciente associada com a atividade de il-20 BRPI0408705A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US45748103P 2003-03-24 2003-03-24
US52329503P 2003-11-17 2003-11-17
PCT/US2004/008955 WO2004085475A2 (en) 2003-03-24 2004-03-24 Anti-il-20 antibodies and binding partners and methods of using in inflammation

Publications (1)

Publication Number Publication Date
BRPI0408705A true BRPI0408705A (pt) 2006-03-07

Family

ID=33101289

Family Applications (2)

Application Number Title Priority Date Filing Date
BRPI0408705-4A BRPI0408705A (pt) 2003-03-24 2004-03-24 método para produzir um anticorpo para um polipeptìdeo, anticorpo produzido pelo mesmo, anticorpo ou fragmento de anticorpo que se liga a um polipeptìdeo, métodos para reduzir ou inibir a proliferação ou diferenciação induzida pela il-20 de células hematopoiéticas e progenitores de célula hematopoiética, para reduzir a inflamação induzida pela il-20, para suprimir uma resposta inflamatória em um mamìfero com inflamação, para tratar um mamìfero afligido com uma doença inflamatória, para tratar um condição patológica em um paciente associada com a atividade de il-20
BRPI0408683-0A BRPI0408683A (pt) 2003-03-24 2004-03-24 métodos de produzir um anticorpo para um polipeptìdeo, anticorpo ou fragmento de anticorpo, método para reduzir ou inibir a proliferação ou diferenciação induzida por il-22 ou induzida por il-20 de células hematopoiéticas e progenitores de células hematopoiéticas, uso de um anticorpo, de uma composição de um anticorpo ou fragmento de anticorpo, uso de um antagonista de il-22 ou il-20, uso de um antagonista de il-22ra

Family Applications After (1)

Application Number Title Priority Date Filing Date
BRPI0408683-0A BRPI0408683A (pt) 2003-03-24 2004-03-24 métodos de produzir um anticorpo para um polipeptìdeo, anticorpo ou fragmento de anticorpo, método para reduzir ou inibir a proliferação ou diferenciação induzida por il-22 ou induzida por il-20 de células hematopoiéticas e progenitores de células hematopoiéticas, uso de um anticorpo, de uma composição de um anticorpo ou fragmento de anticorpo, uso de um antagonista de il-22 ou il-20, uso de um antagonista de il-22ra

Country Status (16)

Country Link
US (6) US20060134756A1 (pt)
EP (2) EP1606316A2 (pt)
JP (2) JP2007525438A (pt)
KR (3) KR20050116392A (pt)
CN (2) CN103864934A (pt)
AT (1) ATE475673T1 (pt)
AU (2) AU2004223837C1 (pt)
BR (2) BRPI0408705A (pt)
CA (2) CA2519057A1 (pt)
DE (1) DE602004028347D1 (pt)
DK (1) DK1606317T3 (pt)
EA (2) EA009124B1 (pt)
ES (1) ES2347657T3 (pt)
MX (2) MXPA05010136A (pt)
NO (1) NO20054892L (pt)
WO (2) WO2004085475A2 (pt)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5965704A (en) * 1997-08-05 1999-10-12 Zymogenetics, Inc. Class two cytokine receptor-11
US6610286B2 (en) 1999-12-23 2003-08-26 Zymogenetics, Inc. Method for treating inflammation using soluble receptors to interleukin-20
ATE342980T1 (de) 2000-08-08 2006-11-15 Zymogenetics Inc Lösliche zcyctor 11 cytokinrezeptoren
DE60141546D1 (de) 2000-09-15 2010-04-22 Zymogenetics Inc Polypeptide enthaltend extrazellulären Domäne von IL-20RA und/oderr IL-20RB
PT1531843E (pt) 2001-12-17 2011-10-27 Zymogenetics Inc Método para tratar o cancro cervical
CA2519057A1 (en) 2003-03-24 2004-10-07 Zymogenetics, Inc. Anti-il-20 antibodies and binding partners and methods of using in inflammation
EP2143733A1 (en) * 2003-11-21 2010-01-13 ZymoGenetics, Inc. ANTI-IL-20 antibodies and binding partners and methods of using in inflammation
US7713737B2 (en) * 2004-10-04 2010-05-11 Trinity Biosystems, Inc. Methods and compositions for needleless delivery of macromolecules
EP1812476B1 (en) * 2004-10-22 2010-07-21 ZymoGenetics, Inc. Anti-il-22ra antibodies and binding partners and methods of using in inflammation
CN100515491C (zh) * 2005-01-04 2009-07-22 健能隆医药技术（上海）有限公司 白介素-22的医药用途
EP2192132A3 (en) * 2005-02-08 2010-08-18 ZymoGenetics, Inc. Anti-IL-20, anti-IL22 and anti-IL-22RA antibodies and binding partners and methods of using in inflammation
NZ621483A (en) * 2005-12-02 2015-10-30 Genentech Inc Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling involving antibodies that bind to il-22 and il-22r
CA2631952A1 (en) * 2005-12-05 2007-06-14 Trinity Biosystems, Inc. Methods and compositions for needleless delivery of antibodies
CA2631981A1 (en) * 2005-12-05 2007-06-14 Trinity Biosystems, Inc. Methods and compositions for needleless delivery of binding partners
US20090148440A1 (en) * 2005-12-22 2009-06-11 Dhy & Co., Ltd. Antibodies against interleukin-22 binding protein and its uses for the treatment of metabolic disorders
CA2647168A1 (en) * 2006-03-16 2007-09-27 Trinity Biosystems, Inc. Methods for increasing the size of animals using needleless delivery constructs
ES2892925T3 (es) 2006-03-31 2022-02-07 Chugai Pharmaceutical Co Ltd Métodos para controlar la farmacocinética en sangre de anticuerpos
PE20080333A1 (es) 2006-06-08 2008-06-15 Chugai Pharmaceutical Co Ltd Agentes para prevenir o tratar enfermedades inflamatorias
US20090092660A1 (en) * 2006-08-09 2009-04-09 Trinity Biosystems, Inc. Methods and compositions for needleless delivery of particles
TWI563002B (en) 2007-09-26 2016-12-21 Chugai Pharmaceutical Co Ltd Antibody constant region mutant
ES2595638T3 (es) 2007-09-26 2017-01-02 Chugai Seiyaku Kabushiki Kaisha Método para modificar el punto isoeléctrico de un anticuerpo mediante la sustitución de aminoácidos en una CDR
TW201634479A (zh) 2007-12-05 2016-10-01 Chugai Pharmaceutical Co Ltd 抗ｎｒ１０抗體及其應用
CN104162155A (zh) 2007-12-05 2014-11-26 中外制药株式会社 搔痒症治疗药
NZ602884A (en) 2008-04-11 2014-08-29 Chugai Pharmaceutical Co Ltd Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
BRPI0914916A2 (pt) 2008-06-30 2015-10-20 Novo Nordisk As anticorpos de interleucina-20 anti-humanos, assim como método de produção dos mesmos
JP2010210772A (ja) * 2009-03-13 2010-09-24 Dainippon Screen Mfg Co Ltd 液晶表示装置の製造方法
WO2010107110A1 (ja) 2009-03-19 2010-09-23 中外製薬株式会社 抗体定常領域改変体
US20120071634A1 (en) 2009-03-19 2012-03-22 Chugai Seiyaku Kabushiki Kaisha Antibody Constant Region Variant
US8454956B2 (en) * 2009-08-31 2013-06-04 National Cheng Kung University Methods for treating rheumatoid arthritis and osteoporosis with anti-IL-20 antibodies
TWI654203B (zh) 2010-11-30 2019-03-21 中外製藥股份有限公司 具有鈣依存性的抗原結合能力之抗體
DK2686347T3 (en) 2011-03-16 2018-06-25 Argenx Bvba Antibodies against CD70
CA2843949C (en) 2011-08-05 2021-01-12 Universite D'aix-Marseille Fibrosis susceptibility il22ra2 gene and uses thereof
US8597647B1 (en) 2012-05-22 2013-12-03 National Cheng Kung University Humanized anti-IL-20 antibody and uses thereof
WO2014006230A1 (en) * 2012-07-06 2014-01-09 Novo Nordisk A/S Il-20 epitopes and il-20 ligands
WO2014015133A1 (en) 2012-07-19 2014-01-23 National Cheng Kung University Treatment of osteoarthritis using il-20 antagonists
US8852588B2 (en) 2012-08-07 2014-10-07 National Cheng Kung University Treating allergic airway disorders using anti-IL-20 receptor antibodies
US8603470B1 (en) 2012-08-07 2013-12-10 National Cheng Kung University Use of IL-20 antagonists for treating liver diseases
CN104583238A (zh) * 2012-08-31 2015-04-29 阿尔金-X有限公司 用于产生具有物种间、靶标内交叉反应性之抗体分子的方法
US10391168B1 (en) 2014-08-22 2019-08-27 University Of Bern Anti-CD70 combination therapy
RU2683020C2 (ru) * 2014-11-11 2019-03-26 Петр Иванович Никитин Субстанция и способ для модуляции активности агента в организме
RU2749512C2 (ru) 2015-04-14 2021-06-11 Чугаи Сейяку Кабусики Кайся Фармацевтическая композиция для профилактики и/или лечения атопического дерматита, включающая антагонист ил-31 в качестве активного ингредиента
CN105601739B (zh) * 2016-02-22 2019-01-18 王晨辉 一种人源化抗白介素22基因工程抗体及其应用
WO2017202813A1 (en) 2016-05-24 2017-11-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of pulmonary bacterial infections
GB201612337D0 (en) * 2016-07-15 2016-08-31 Argen-X N V Ant-il-22r antibodies
JOP20190155A1 (ar) 2016-12-21 2019-06-23 Novartis Ag مترافقات عقار جسم مضاد لإزالة خلايا جذعية مكونة للدم
GB201800649D0 (en) 2018-01-16 2018-02-28 Argenx Bvba CD70 Combination Therapy
WO2020210816A1 (en) * 2019-04-12 2020-10-15 Methodist Hospital Research Institute Therapeutic particles that enable antigen presenting cells to attack cancer cells
EP3984553A4 (en) * 2019-06-12 2023-07-19 Acurasysbio Co., Ltd. COMPOSITION FOR THE PREVENTION OR TREATMENT OF CANCER
TWI860426B (zh) 2019-11-20 2024-11-01 日商中外製藥股份有限公司 含有抗體之製劑

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3654090A (en) 1968-09-24 1972-04-04 Organon Method for the determination of antigens and antibodies
US4331647A (en) * 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
DE3572982D1 (en) 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
NZ212437A (en) * 1985-06-17 1992-06-25 Mark Philip Best Site-directed antibody conjugates, and their preparation
WO1989004838A1 (en) * 1987-11-25 1989-06-01 Immunex Corporation Interleukin-1 receptors
US4847325A (en) 1988-01-20 1989-07-11 Cetus Corporation Conjugation of polymer to colony stimulating factor-1
US5567584A (en) * 1988-01-22 1996-10-22 Zymogenetics, Inc. Methods of using biologically active dimerized polypeptide fusions to detect PDGF
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5436155A (en) * 1991-12-31 1995-07-25 Arch Development Corporation Isolated DNA encoding a somatostatin receptor
US5789192A (en) * 1992-12-10 1998-08-04 Schering Corporation Mammalian receptors for interleukin-10 (IL-10)
WO1995021258A1 (en) 1994-02-01 1995-08-10 United States Of America, Represented By The Secretary, Department Of Health And Human Services Fusion proteins that include antibody and nonantibody portions
WO2000077037A2 (en) 1999-06-15 2000-12-21 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
JP3713074B2 (ja) * 1995-08-30 2005-11-02 栄研化学株式会社 血清アミロイドａを認識するモノクローナル抗体
US5843697A (en) 1996-07-17 1998-12-01 University Of Medicine And Dentistry Of New Jersey Cells expressing IL-10 receptor and the CRFB4 gene product, an IL-10 receptor accessory protein
US5985614A (en) * 1996-08-30 1999-11-16 Human Genome Sciences, Inc. Polynucleotides encoding interleukin-19
US5945511A (en) 1997-02-20 1999-08-31 Zymogenetics, Inc. Class II cytokine receptor
US6133426A (en) * 1997-02-21 2000-10-17 Genentech, Inc. Humanized anti-IL-8 monoclonal antibodies
WO2000078961A1 (en) 1999-06-23 2000-12-28 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
JP2001510035A (ja) 1997-07-16 2001-07-31 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド インターロイキン−２０
US6486301B1 (en) 1997-07-16 2002-11-26 Human Genome Sciences, Inc. Interleukin-20
KR100236609B1 (ko) * 1997-08-01 2000-02-01 박호군 클로로하이드로실란 유도체 및 이의 제조방법
US5965704A (en) * 1997-08-05 1999-10-12 Zymogenetics, Inc. Class two cytokine receptor-11
AU8899298A (en) * 1997-08-06 1999-03-01 Zymogenetics Inc. Lipocalin homologs
US6551799B2 (en) * 1999-12-07 2003-04-22 Genentech, Inc. Interleukin-22 polypeptides, nucleic acids encoding the same and methods for the treatment of pancreatic disorders
UA86350C2 (en) * 1997-11-26 2009-04-27 Займодженетикс, Инк Normal;heading 1;heading 2;MAMMALIAN CYTOKINE-LIKE POLYPEPTIDE-10
US6576743B1 (en) * 1997-11-26 2003-06-10 Zymogenetics, Inc. Mammalian cytokine-like polypeptide-10
DE69918946T2 (de) 1998-01-23 2005-07-28 Immunex Corp., Seattle Rezeptoren für il-18
JP2002505879A (ja) 1998-03-09 2002-02-26 シェーリング コーポレイション ヒトレセプタータンパク質；関連する試薬および方法
PT1490386E (pt) 1998-03-10 2008-11-24 Genentech Inc Novos polipéptidos e ácidos nucleicos que os codificam
US6197582B1 (en) * 1998-03-18 2001-03-06 The Trustees Of Columbia University In The City Of New York Development of human monoclonal antibodies and uses thereof
US6982320B2 (en) 1998-03-19 2006-01-03 Human Genome Sciences, Inc. Cytokine receptor common gamma chain like
AU5203199A (en) 1998-05-26 1999-12-13 Procter & Gamble Company, The Chimeric molecules comprising an extracellular ligand binding domain of a receptor and an ige fc or constant region, and their use in an assay system
NZ510464A (en) 1998-09-01 2004-05-28 Genentech Inc Further pro polypeptides and sequences thereof
AU760224B2 (en) 1998-10-26 2003-05-08 Wyeth Isolated nucleic acid molecules which encode T cell inducible factors (TIFs), the proteins encoded, and uses thereof
US6274710B1 (en) * 1998-10-26 2001-08-14 Ludwig Institute For Cancer Research Antibodies which specifically bind T Cell inducible factors (TIFs)
WO2000039161A1 (en) 1998-12-31 2000-07-06 Millennium Pharmaceuticals, Inc. Class ii cytokine receptor-like proteins and nucleic acids encoding them
BR0010097A (pt) 1999-04-28 2002-02-13 Genetics Inst Polinucleotìdeo isolado; célula hospedeira; processo para a produção de uma proteìna codificada pelo polinucleotìdeo; proteìna; composição; e; anticorpo
EP1179066A2 (en) 1999-05-19 2002-02-13 Incyte Genomics, Inc. Extracellular signaling molecules
AU5047600A (en) 1999-05-27 2000-12-18 Schering Corporation Mammalian interleukin-10 homologs: il-d110 and il-d210
CA2378519C (en) 1999-07-07 2011-01-25 Zymogenetics, Inc. Human cytokine receptor
AU7573000A (en) 1999-09-01 2001-03-26 Genentech Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
CA2392109A1 (en) 1999-11-18 2001-05-25 Schering Corporation Mammalian receptor proteins; related reagents and methods
JP2003534773A (ja) 1999-12-03 2003-11-25 ザイモジェネティクス，インコーポレイティド ヒトサイトカイン受容体
ATE459369T1 (de) * 1999-12-23 2010-03-15 Zymogenetics Inc Verfahren zur behandlung von entzündungen
CA2395369C (en) 1999-12-23 2014-07-08 Zymogenetics, Inc. Cytokine zcyto18
US6610286B2 (en) * 1999-12-23 2003-08-26 Zymogenetics, Inc. Method for treating inflammation using soluble receptors to interleukin-20
UA84830C2 (uk) 1999-12-23 2008-12-10 Займодженетікс, Інк. Розчинний рецептор інтерлейкіну-20
NZ523122A (en) 2000-06-22 2004-06-25 Smithkline Beecham Corp Polypeptides and polynucleotides and methods of identifying agonists and antagonists in relation to treatment of diseases
JP2002015498A (ja) * 2000-06-29 2002-01-18 Fujitsu Ltd センス電流の設定方法
ATE342980T1 (de) 2000-08-08 2006-11-15 Zymogenetics Inc Lösliche zcyctor 11 cytokinrezeptoren
WO2002020569A2 (en) 2000-09-08 2002-03-14 Schering Corporation Mammalian genes; related reagents and methods
DE60141546D1 (de) 2000-09-15 2010-04-22 Zymogenetics Inc Polypeptide enthaltend extrazellulären Domäne von IL-20RA und/oderr IL-20RB
US7268223B2 (en) 2000-09-22 2007-09-11 Wyeth Isolated nucleic acid molecules which encode a soluble IL-TIF receptor or binding protein which binds to IL-TIF/IL-22, and uses thereof
US20030022827A1 (en) 2000-09-25 2003-01-30 Bertram Weiss Three new members of the cytokine receptor family class 2
MXPA03006218A (es) 2001-01-12 2004-09-13 Inst Genetics Llc Receptor de citosina tipo 2 y acidos nucleicos que codifican para lo mismo.
WO2002058724A2 (en) 2001-01-26 2002-08-01 Eli Lilly And Company Use of lp82 to treat body weight disorders
BR0207528A (pt) 2001-02-23 2006-01-17 Inst Genetics Llc Anticorpo, composição farmacêutica, e, usos de uma quantidade efetiva de um agente, de uma quantidade terapeuticamente efetiva de um anticorpo para il-22, de uma quantidade imunogênica do antìgeno e uma quantidade aumentadora de imunogenicidade de il-22 em combinação, de uma quantidade efetiva do anticorpo ou fragmento do mesmo e de uma quantidade suficiente de anticorpo ou fragmento ligado a antìgeno do mesmo
JP2005506287A (ja) * 2001-02-28 2005-03-03 イーライ・リリー・アンド・カンパニー 造血障害を治療するためのｌｐ８２の使用
WO2002070655A2 (en) 2001-03-02 2002-09-12 Zymogenetics, Inc. Mouse cytokine receptor
WO2002072607A2 (en) * 2001-03-09 2002-09-19 Zymogenetics, Inc. Soluble heterodimeric cytokine receptor
US20030099608A1 (en) 2001-03-27 2003-05-29 Presnell Scott R. Human cytokine receptor
WO2002092771A2 (en) * 2001-05-11 2002-11-21 Ludwig Institute For Cancer Research Specific binding proteins and uses thereof
WO2003035096A1 (en) 2001-10-22 2003-05-01 Eli Lilly And Company Soluble proteins that inhibit cytokine signal transduction pathways
DE10154579A1 (de) 2001-11-07 2003-05-28 Medigene Ag Topikale Verwendung von Cytokinen und Chemokinen zur Behandlung von viralen oder mykotischen Hauterkrankungen oder Tumorerkrankungen
PT1531843E (pt) 2001-12-17 2011-10-27 Zymogenetics Inc Método para tratar o cancro cervical
US20040236075A1 (en) 2002-07-24 2004-11-25 Laure Dumoutier Novel glass II cytokine receptors, and uses thereof
CA2519057A1 (en) 2003-03-24 2004-10-07 Zymogenetics, Inc. Anti-il-20 antibodies and binding partners and methods of using in inflammation
CN1845937A (zh) * 2003-03-24 2006-10-11 津莫吉尼蒂克斯公司 抗il－20抗体和结合伴侣以及在炎症中的使用方法
EP2143733A1 (en) 2003-11-21 2010-01-13 ZymoGenetics, Inc. ANTI-IL-20 antibodies and binding partners and methods of using in inflammation
EP1812476B1 (en) * 2004-10-22 2010-07-21 ZymoGenetics, Inc. Anti-il-22ra antibodies and binding partners and methods of using in inflammation

Also Published As

Publication number Publication date
US8163286B2 (en) 2012-04-24
US20120207761A1 (en) 2012-08-16
BRPI0408683A (pt) 2006-03-28
KR20050116392A (ko) 2005-12-12
EA009124B1 (ru) 2007-10-26
ATE475673T1 (de) 2010-08-15
US20080233115A1 (en) 2008-09-25
ES2347657T3 (es) 2010-11-03
EP1606317A2 (en) 2005-12-21
WO2004085475A3 (en) 2005-07-14
AU2004223836A1 (en) 2004-10-07
KR20110091598A (ko) 2011-08-11
EA200501505A1 (ru) 2006-06-30
DE602004028347D1 (de) 2010-09-09
CA2519089A1 (en) 2004-10-07
AU2004223837A2 (en) 2004-10-07
EA009026B1 (ru) 2007-10-26
JP2007525438A (ja) 2007-09-06
KR20050116390A (ko) 2005-12-12
CN102690350A (zh) 2012-09-26
AU2004223837A1 (en) 2004-10-07
CA2519057A1 (en) 2004-10-07
EP1606316A2 (en) 2005-12-21
AU2004223836A2 (en) 2004-10-07
JP2007525437A (ja) 2007-09-06
MXPA05010136A (es) 2005-11-16
EP1606317B1 (en) 2010-07-28
WO2004085476A3 (en) 2005-03-31
AU2004223837C1 (en) 2012-03-15
CA2519089C (en) 2014-12-23
WO2004085475A2 (en) 2004-10-07
NO20054892D0 (no) 2005-10-21
DK1606317T3 (da) 2010-10-25
US20100111948A1 (en) 2010-05-06
MXPA05010134A (es) 2005-11-16
CN103864934A (zh) 2014-06-18
US20090074661A1 (en) 2009-03-19
US20060134756A1 (en) 2006-06-22
EA200501506A1 (ru) 2006-06-30
US20040209330A1 (en) 2004-10-21
NO20054892L (no) 2005-12-23
AU2004223837B2 (en) 2011-04-21
WO2004085476A2 (en) 2004-10-07

Similar Documents

Publication Publication Date Title
BRPI0408705A (pt) método para produzir um anticorpo para um polipeptìdeo, anticorpo produzido pelo mesmo, anticorpo ou fragmento de anticorpo que se liga a um polipeptìdeo, métodos para reduzir ou inibir a proliferação ou diferenciação induzida pela il-20 de células hematopoiéticas e progenitores de célula hematopoiética, para reduzir a inflamação induzida pela il-20, para suprimir uma resposta inflamatória em um mamìfero com inflamação, para tratar um mamìfero afligido com uma doença inflamatória, para tratar um condição patológica em um paciente associada com a atividade de il-20
IL207146A0 (en) Antibodies capable of competing with anti-il-22ra monoclonal antibodies
BRPI0511952A (pt) receptor solúvel isolado, anticorpo ou fragmento de anticorpo, e, métodos de reduzir inflamação induzida por il-17a ou induzida por il-17f, de tratar um mamìfero afetado com uma doença inflamatória, e uma condição patológica em um indivìduo associada com atividade de zcytor14
RU2008126932A (ru) Составы и способы лечения заболеваний и нарушений, связанных с передачей сигналов цитокинами
EA200500647A1 (ru) Антитела, связывающие клеточные полипептиды ca 125/0772p, и способы их применения
EA201000245A1 (ru) Человеческие нейтрализующие антитела к фактору роста нервов (ngf) в качестве селективных ингибиторов метаболического пути ngf
ES2137354T3 (es) Moleculas de anticuerpo anti-vla4 recombinante.
WO2005052000A3 (en) Anti-il-20 antibodies and binding partners and methods of using in inflammation
Al‐Samadi et al. IL‐17 C and its receptor IL‐17 RA/IL‐17 RE identify human oral epithelial cell as an inflammatory cell in recurrent aphthous ulcer
EE200700052A (et) Antikeha he v?i mitme apo-lipoproteiin B fragmendi vastu
Bae et al. Periostin and interleukin-13 are independently related to chronic spontaneous urticaria
Giusti et al. Biomarkers related to bullous pemphigoid activity and outcome
Matsumoto et al. Noticeable decreased expression of tenascin-X in calcific aortic valves
Watanabe et al. Increased level of high mobility group box 1 in the serum and skin in patients with generalized pustular psoriasis
WO2005086568A3 (en) Anti-icam-1 human antibodies and uses thereof
WO2024030956A3 (en) Cd39-specific binding agents and methods of using the same
BRPI0516603A (pt) receptor solúvel isolado, anticorpo ou fragmento de anticorpo, e, métodos para tratar uma doença imuno-mediada em um paciente em necessidade de tal tratamento, para reduzir a inflamação mediada pela il-17c, para tratar um mamìfero afligido com uma doença inflamatória, e para tratar uma condição patológica em um paciente associada com a atividade de zcytor21
Wang et al. Seawater immersion exacerbates the pathological changes caused by incisive corneal injury in rabbit eyes
Xu et al. AB0098 THE CAUSAL RELATIONSHIP BETWEEN MULTIPLE SCLEROSIS AND PSORIASIS: A TWO-SAMPLE MENDELIAN RANDOMIZED STUDY
Kudryashov et al. AB0021 FEATURES OF IMMUNOLOGICAL MANIFESTATIONS OF СOMMON VARIABLE IMMUNODEFICIENCY COMBINED WITH RHEUMATOID ARTHRITIS
Bittar et al. Increased levels of endothelial dysfunction markers and matrix metalloproteinases in patients with severe post-thrombotic syndrome
Navarrete et al. AB0020 COMPARATIVE DESCRIPTION OF CYTOKINES AND MATRIX METALLOPROTEINASES IN A GROUP OF PATIENTS WITH RHEUMATOID ARTHRITIS AND OSTEOARTHROSIS UNDER A STRICT FOLLOW-UP COMPARED WITH COVID-19 PATIENTS
US20160252519A1 (en) In-vitro method for determining fate of polypeptide variant
Bae Youin et al. Periostin and interleukin-13 are independently related to chronic spontaneous urticaria.
MA37523B1 (fr) Protéines de liaison à l'antigène st2

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B11T Dismissal of application maintained [chapter 11.20 patent gazette]